Table 1.
Characteristics at registration for all ‘registration cohort’ patients, split by metastatic status at registration (N = 2186).
| Patient characteristic | M0a at registration |
M1 at registration |
Metastases status at registration not known |
Total |
||||
|---|---|---|---|---|---|---|---|---|
| N | % | N | % | N | % | N | % | |
| Age at registrationb | ||||||||
| Child | 536 | 30 | 115 | 32 | 6 | 43 | 657 | 30 |
| Adolescent | 900 | 50 | 168 | 46 | 7 | 50 | 1075 | 49 |
| Adult | 374 | 21 | 79 | 22 | 1 | 7 | 454 | 21 |
| Gender | ||||||||
| Male | 1050 | 58 | 230 | 64 | 5 | 36 | 1285 | 59 |
| Female | 760 | 42 | 132 | 36 | 9 | 64 | 901 | 41 |
| Site of the tumour | ||||||||
| Proximal femur/humerus | 227 | 13 | 55 | 15 | 0 | 0 | 282 | 13 |
| Other limb site | 1489 | 82 | 295 | 82 | 0 | 0 | 1784 | 82 |
| Axial skeleton | 94 | 5 | 12 | 3 | 0 | 0 | 106 | 5 |
| Missing | 0 | 0 | 0 | 0 | 14 | 100 | 14 | 1 |
| Location on the bone | ||||||||
| Proximal | 712 | 39 | 144 | 40 | 1 | 7 | 857 | 39 |
| Diaphysis | 73 | 4 | 19 | 5 | 0 | 0 | 92 | 4 |
| Distal | 917 | 51 | 184 | 51 | 0 | 0 | 1101 | 50 |
| Not long bone, n/a | 103 | 6 | 12 | 3 | 0 | 0 | 115 | 5 |
| Missing | 5 | 0 | 3 | 1 | 13 | 93 | 21 | 1 |
| WHO classification of sarcoma at diagnostic biopsy | ||||||||
| Conventional: chondroblastic | 303 | 17 | 39 | 11 | 1 | 7 | 343 | 16 |
| Conventional: osteoblastic | 1051 | 58 | 246 | 68 | 8 | 57 | 1305 | 60 |
| Conventional: other | 298 | 16 | 52 | 14 | 5 | 36 | 355 | 16 |
| Telangiectatic | 84 | 5 | 11 | 3 | 0 | 0 | 95 | 4 |
| Small cell | 9 | 1 | 2 | 1 | 0 | 0 | 11 | 1 |
| High-grade surface | 25 | 1 | 2 | 1 | 0 | 0 | 27 | 1 |
| Missing | 40 | 2 | 10 | 3 | 0 | 0 | 50 | 2 |
| Relative tumour volume | ||||||||
| Small (<1/3 of involved bone) | 848 | 47 | 110 | 30 | 1 | 7 | 959 | 44 |
| Large (≥1/3 of involved bone) | 638 | 35 | 177 | 49 | 0 | 0 | 815 | 37 |
| Missing | 324 | 18 | 75 | 21 | 13 | 93 | 412 | 19 |
| Pathological fracture at diagnosis | ||||||||
| No | 1594 | 88 | 308 | 85 | 1 | 7 | 1903 | 87 |
| Yes | 213 | 12 | 54 | 15 | 0 | 0 | 267 | 12 |
| Missing | 3 | 0 | 0 | 0 | 13 | 93 | 16 | 1 |
| Surgical margins achievedc | ||||||||
| Wide/Radical | 1357 | 75 | 257 | 71 | 13 | 93 | 1627 | 74 |
| Marginal | 218 | 21 | 34 | 9 | 0 | 0 | 252 | 12 |
| Intralesional | 23 | 1 | 3 | 1 | 0 | 0 | 26 | 1 |
| Missing | 212 | 12 | 68 | 19 | 1 | 7 | 281 | 13 |
| Duration of symptoms (weeks) | ||||||||
| Median (IQR) | 8 | 8 | – | 8 | ||||
| Min–max | 0–312 | 0–67 | – | 0–312 | ||||
| N | 1596 | 324 | 1d | 1921 | ||||
| Total | 1810 | 100 | 362 | 100 | 14 | 100 | 2186 | 100 |
IQR, interquartile range; WHO, World Health Organisation.
a
includes possible metastases.
b
age groups defined according to Collins et al.: child (0–12 for males and 0–11 for females), adolescent (13–17 for males and 12–16 for females) and adult (≥18 for males and ≥17 for females).
c
as reported by the pathologist.
d
data not presented because duration of symptoms is known for only one patient in this group.